{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:04:21Z","timestamp":1792242261145,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic insomnia disorder (CID) significantly impacts well-being and daily functioning. Daridorexant, a double orexin receptor blocker, has shown efficacy in randomized clinical trials and has been recently approved for the treatment of CID in adult patients. This retrospective observational study aimed to describe real-world data on daridorexant effectiveness and safety in adult patients with CID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive patients initiating on-label daridorexant at the Sleep Medicine Centre, University Hospital of Rome Tor Vergata were enrolled. Baseline and 30-day follow-up (FU) evaluations included patients\u2019 and CID characteristics, comorbidities, and clinicians\u2019 and patients\u2019 subjective ratings of changes with the Clinical and Patient Global Impression-Improvement scores (CGI-Is and PGI-Is), as well as Insomnia Severity Index (ISI) scores in a subgroup of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty-nine patients initiated 50-mg daily dosage. At FU, 58% of both patients and clinicians rated CID as improved on CGI-Is and PGI-Is, with no differences based on comorbidities, sex, or number of previous medications. No significant predictors of CGI-Is and PGI-Is improvement were identified. At FU, ISI scores (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) significantly decreased from 18.25\u2009\u00b1\u20093.21 to 12.08\u2009\u00b1\u20096.12 (\n                      <jats:italic>Z<\/jats:italic>\n                      \u2009=\u20098.000;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Of these, eight patients (33.3%) had absence of insomnia symptoms, and no patients reported a worsening in ISI score categories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests daridorexant to be effective and safe in real-world CID treatment whether used as a first-ever treatment, switch, or add-on, as reflected by subjective and objective measures and the absence of serious treatment-related adverse events. Future research on larger cohorts should explore daridorexant potential across diverse patient characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-024-07326-w","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T06:02:21Z","timestamp":1706335341000},"page":"3443-3448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-2805","authenticated-orcid":false,"given":"Mariana","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Placidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"issue":"7","key":"7326_CR1","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1111\/ene.14784","volume":"28","author":"L Ferini-Strambi","year":"2023","unstructured":"Ferini-Strambi L, Auer R, Bjorvatn B, Castronovo V, Franco O, Gabutti L, Galbiati A, Hajak G, Khatami R, Kitajima T, McEvoy D, Nissen C, Perlis M, Pevernagie DA, Randerath W, Riemann D, Rizzo G, Van Someren E, Vgontzas A et al (2023) Insomnia disorder: clinical and research challenges for the 21st century. Eur J Neurol 28(7):2156\u20132167","journal-title":"Eur J Neurol"},{"issue":"15","key":"7326_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/NSS.S201994","volume":"22","author":"MP Mogavero","year":"2023","unstructured":"Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R (2023) Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to current clinical evidence and recommendations. Nat Sci Sleep 22(15):17\u201338. https:\/\/doi.org\/10.2147\/NSS.S201994","journal-title":"Nat Sci Sleep"},{"key":"7326_CR3","unstructured":"Idorsia Pharmaceuticals Ltd. QUVIVIQ Canada Product Monograph. Available from: https:\/\/www.idorsia.com\/documents\/com\/label\/quviviq-product-monograph.pdf. Accessed 3 Oct 2023"},{"key":"7326_CR4","unstructured":"Idorsia Pharmaceuticals Ltd. QUVIVIQ Public Summary SwissPAR. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/about-us\/publications\/public-summary-swiss-par\/public-summary-swiss-par-quviviq.html. Accessed 3 Oct 2023"},{"key":"7326_CR5","unstructured":"Idorsia Pharmaceuticals Ltd. QUVIVIQ SmPC. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/85c62eba3cf0011439721e4b802d79aa161eac19. Accessed 3 Oct 2023"},{"key":"7326_CR6","unstructured":"Idorsia Pharmaceuticals Ltd. QUVIVIQ SmPC. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/quviviq-epar-product-information_en.pdf. Accessed 3 Oct 2023"},{"key":"7326_CR7","unstructured":"Idorsia Pharmaceuticals Ltd. QUVIVIQ USPI. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf. Accessed 3 Oct 2023"},{"key":"7326_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13902","volume":"22","author":"C Muehlan","year":"2023","unstructured":"Muehlan C, Roch C, Vaillant C, Dingemanse J (2023) The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res 22:e13902. https:\/\/doi.org\/10.1111\/jsr.13902","journal-title":"J Sleep Res"},{"issue":"7","key":"7326_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032754","volume":"102","author":"F Jiang","year":"2023","unstructured":"Jiang F, Li H, Chen Y, Lu H, Ni J, Chen G (2023) Daridorexant for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 102(7):e32754. https:\/\/doi.org\/10.1097\/MD.0000000000032754","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"7326_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T (2022) Investigators. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 21(2):125\u2013139. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1 (Erratum in: Lancet Neurol. 2022 Jan 20; Erratum in: Lancet Neurol. 2022 Jun;21(6):e6)","journal-title":"Lancet Neurol"},{"issue":"3","key":"7326_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J (2020) Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol 87(3):347\u2013356. https:\/\/doi.org\/10.1002\/ana.25680 (Erratum in: Ann Neurol.;88(3):647\u2013651)","journal-title":"Ann Neurol"},{"issue":"21","key":"7326_CR12","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","volume":"94","author":"G Zammit","year":"2020","unstructured":"Zammit G, Dauvilliers Y, Pain S, Seb\u00f6kKinter D, Mansour Y, Kunz D (2020) Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology 94(21):e2222\u2013e2232. https:\/\/doi.org\/10.1212\/WNL.0000000000009475","journal-title":"Neurology"},{"issue":"4","key":"7326_CR13","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jagp.2022.01.064","volume":"30","author":"I Fietze","year":"2022","unstructured":"Fietze I, Bassetti C, Mayleben D, Gimona A, Pain S, McCall W, Kinter DS (2022) Effects of daridorexant on sleep and daytime functioning in older adults with insomnia. Am J Geriatr Psychiatry 30(4):S69\u2013S70","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"7326_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","volume":"37","author":"D Kunz","year":"2023","unstructured":"Kunz D, Dauvilliers Y, Benes H, Garcia-Borreguero D, Plazzi G, SeboekKinter D, Coloma P, Rausch M, Sassi-Sayadi M, Thein S (2023) Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs 37(1):93\u2013106","journal-title":"CNS Drugs"},{"issue":"9","key":"7326_CR15","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/jcm12093240","volume":"12","author":"SG Williams","year":"2023","unstructured":"Williams SG, Rodriguez-Cu\u00e9 D (2023) Use of daridorexant among patients with chronic insomnia: a retrospective observational analysis. J Clin Med 12(9):3240. https:\/\/doi.org\/10.3390\/jcm12093240","journal-title":"J Clin Med"},{"key":"7326_CR16","volume-title":"Abstract presented at the World Sleep Congress 2023, October 20 \u2013 25, Rio de Janeiro, Brazil","author":"Y Winter","year":"2023","unstructured":"Winter Y, Apel D, Groppa S (2023) Influence of daridorexant on the health-related quality of life in patients with chronic insomnia. In: Abstract presented at the World Sleep Congress 2023, October 20 \u2013 25, Rio de Janeiro, Brazil"},{"key":"7326_CR17","volume-title":"Abstract presented at the World Sleep Congress 2023, October 20 \u2013 25, Rio de Janeiro, Brazil","author":"L Palagini","year":"2023","unstructured":"Palagini L, Alfi G, Gurrieri R, Caruso V, Trivella M, Annuzzi E, Gambini M, Grenno G, Miniati M, Gemignani A (2023) Early experience with the new DORA daridorexant in patients with insomnia disorder: results of a real world study with a 3 months follow up period. In: Abstract presented at the World Sleep Congress 2023, October 20 \u2013 25, Rio de Janeiro, Brazil"},{"issue":"1","key":"7326_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-019-0571-3","volume":"12","author":"C Liguori","year":"2020","unstructured":"Liguori C, Placidi F, Izzi F, Spanetta M, Mercuri NB, Di Pucchio A (2020) Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer\u2019s disease course. Alzheimers Res Ther 12(1):5. https:\/\/doi.org\/10.1186\/s13195-019-0571-3 (Erratum.In:AlzheimersResTher.2020May8;12(1):53)","journal-title":"Alzheimers Res Ther"},{"key":"7326_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2016.01.007","volume":"40","author":"C Liguori","year":"2016","unstructured":"Liguori C, Nuccetelli M, Izzi F, Sancesario G, Romigi A, Martorana A, Amoroso C, Bernardini S, Marciani MG, Mercuri NB, Placidi F (2016) Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer\u2019s disease. Neurobiol Aging 40:120\u2013126. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.01.007","journal-title":"Neurobiol Aging"},{"issue":"12","key":"7326_CR20","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","volume":"71","author":"C Liguori","year":"2014","unstructured":"Liguori C, Romigi A, Nuccetelli M, Zannino S, Sancesario G, Martorana A, Albanese M, Mercuri NB, Izzi F, Bernardini S, Nitti A, Sancesario GM, Sica F, Marciani MG, Placidi F (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71(12):1498\u20131505. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2510","journal-title":"JAMA Neurol"},{"issue":"8","key":"7326_CR21","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/epi.17661","volume":"64","author":"C Berteotti","year":"2023","unstructured":"Berteotti C, Calvello C, Liguori C (2023) Role of the orexin system in the bidirectional relation between sleep and epilepsy: new chances for patients with epilepsy by the antagonism to orexin receptors? Epilepsia 64(8):1991\u20132005. https:\/\/doi.org\/10.1111\/epi.17661","journal-title":"Epilepsia"},{"issue":"245","key":"7326_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109815","volume":"17","author":"M Carpi","year":"2023","unstructured":"Carpi M, Palagini L, Fernandes M, Calvello C, Geoffroy PA, Miniati M, Pini S, Gemignani A, Mercuri NB, Liguori C (2023) Clinical usefulness of dual orexin receptor antagonism beyond insomnia: neurological and psychiatric comorbidities. Neuropharmacology 17(245):109815. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109815","journal-title":"Neuropharmacology"},{"key":"7326_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif PE et al (2018) Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther 104:1022\u20131029","journal-title":"Clin Pharmacol Ther"},{"key":"7326_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Brooks S, Zuiker R et al (2019) Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol 29:847\u2013857","journal-title":"Eur Neuropsychopharmacol"},{"key":"7326_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101332","volume":"53","author":"JW Clark","year":"2020","unstructured":"Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH (2020) Effects of orexin receptor antagonism on human sleep architecture: a systematic review. Sleep Med Rev 53:101332. https:\/\/doi.org\/10.1016\/j.smrv.2020.101332","journal-title":"Sleep Med Rev"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07326-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T21:02:09Z","timestamp":1718312529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["7326"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07326-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present investigation is part of the \u201cDORMI 2023\u201d study and was approved by the Ethical Committee of our center (identification code 52.23). All involved patients signed an informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Claudio Liguori participated in speaker or advisory board meetings and received consultantship and research funding from Idorsia; no other conflicts of interest related to this work are present. The other authors declare no conflicts of interest related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}